• Worldwide agreement with Polpharma Biologics gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis (RRMS)
• RRMS affects ~85% of MS patients and can create a substantial social and economic burden on patients, their families and healthcare systems[1],[2]
• Natalizumab is fifth proposed biosimilar in-licensed by Sandoz in nine months, underscoring commitment to further grow pipeline through collaborations

Holzkirchen, Germany, September 3, 2019 …